Trial Details
RECRUITINGBasic Information
| Clinical ID | c488 |
|---|---|
| Identifier | NCT06548542 |
| Trial Title | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Risankizumab|DRUG: Lutikizumab|DRUG: Trosunilimab|DRUG: Risankizumab|DRUG: Trosunilimab|DRUG: ABBV-8736 |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Dothan |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2024-09-04 |
|---|---|
| Primary Completion Date | 2027-12 |
| Completion Date | 2028-08 |